- For Print
- December 6, 2007
Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito) today hosted the ground-breaking ceremony to commemorate the beginning of construction of “Eisai Pharmatechnology & Manufacturing Private Limited”(“EPM”), Eisai's newly established manufacturing and research subsidiary in Andhra Pradesh state in south India.
Aiming to start manufacturing and research activities in 2010, the new API and dosage form manufacturing facility with research function will be constructed in 50-acres land in Jawaharlal Nehru Pharma City SEZ located in Visakhapatnam, Andhra Pradesh in south India.
This establishment is a part of Eisai's transformation strategy to transfer some of the Company's primary operation functions to the areas with high technologies standard aiming for reinforcement of its global flexibility to realize “Dramatic Leap Plan” (5th mid-term strategic plan). The new facility for API and Dosage form manufacturing and research will synergise the Eisai's global effort for its DLP goal, which is to achieve the net sales of 1 trillion yen and 15% in cost to sales ratio in FY 2011. It is also expected to support Eisai's global logistic infrastructure with Kashima Plant.
Eisai continues to promote hhc philosophy, our corporate mission, and contribute to patients and their family all over the world through discovering novel compounds and stable supply of our high quality products on a global basis.
Corporate Communications Department
Eisai Co., Ltd.
*You can scroll to the left or right here
|Company Name:||Eisai Pharmatechnology & Manufacturing Private Limited|
|Date of Establishment:||March 22, 2007|
|Capital:||268 million Rupee (approx. 777 million yen)|
|Location:||Jawaharlal Nehru Pharma City, Visakhapatnam, Andhra Pradesh, India.|
|President:||Sanjit Singh Lamba|
|Major Operation:||Manufacturing and research of APIs and dosage forms|